This page is reference information only. Most compounds described here are research chemicals, not FDA-approved medications. MyTRT does not sell, recommend, or endorse the use of these substances. Always consult a qualified physician.
LL-37
Host-Defense Antimicrobial Peptide
/WHAT_IT_IS
LL-37 (Human Cathelicidin) is the C-terminal, active form of the human cathelicidin (hCAP18). It exhibits broad-spectrum antimicrobial activity and immunomodulatory effects, and is studied for roles in wound repair, biofilm disruption, and epithelial barrier defense.
/USAGE
Used in research on chronic wounds, skin/mucosal defense, biofilm-related infections, and innate immunity signaling.
/MECHANISM_OF_ACTION
Disrupts microbial membranes via amphipathic helical insertion; modulates TLR signaling and cytokine/chemokine release; promotes keratinocyte migration/angiogenesis and can neutralize LPS to reduce endotoxin-driven inflammation.
Reported Benefits
- +Broad-spectrum antimicrobial and anti-biofilm activity
- +Supports wound closure and re-epithelialization
- +Enhances local immune surveillance and barrier function
- +LPS neutralization and modulation of inflammatory signaling
Reported Side Effects
- −Local irritation, burning, or erythema at application site
- −Pro-inflammatory effects at higher concentrations
- −Potential flare of inflammatory dermatoses (e.g., psoriasis models)
- −Rare hypersensitivity reactions
/STACKED_WITH
/RESEARCH_NOTES
Activity is concentration- and matrix-dependent; excessive dosing may shift toward irritation/inflammation. Anti-biofilm effects noted against common wound pathogens. Consider protease-rich environments (e.g., chronic wounds) when designing formulations to limit rapid degradation.
/RELATED
Browse all 89 in the app.
MyTRT's in-app library has the same 89 peptide entries plus dosing notes, stack builders, and the ability to log them alongside your TRT protocol.